Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

LHON

- PMLiVE

CHMP turns down drugs for MS, cancer and muscular dystrophy

Negative EU recommendations for Teva, AB Science and PTC Therapeutics

Novartis building

CHMP denies Novartis’ heart failure drug

Panel refuses to recommend serelaxin for use in EU

- PMLiVE

GSK’s diabetes drug among CHMP recommendations

EMA committee also backs drugs from Bayer, Takeda and Linepharma France

Novartis building

CHMP backs Xolair for severe hives

Novartis set to expand indications for asthma drug

Daiichi Sankyo logo

Daiichi files new anticoagulant edoxaban in US and EU

Seeks approvals in atrial fibrillation and venous thromboembolism

Sanofi reception

Sanofi strikes $700m rare diseases deal

Company's Genzyme division will obtain significant rights to Alnylam’s pipeline of orphan drugs

Novartis building

Novartis myeloma drug clears phase III trial

Panobinostat on course to be first in new class of treatment for bone marrow cancer

- PMLiVE

European Court may yet force AbbVie and InterMune to release data

Orders rethink on EMA's Humira and Esbriet injunction

- PMLiVE

Pfizer ups the ante on clinical transparency

Revamps access to data portal

- PMLiVE

EMA: more fee reductions for orphan drugs

Greater incentives introduced for larger companies

- PMLiVE

ViiV’s Tivicay for HIV on course for EU approval

More positive news for GSK, Pfizer and Shionogi joint venture

- PMLiVE

BMS/AZ’s diabetes drug among CHMP recommendations

Xigduo one of six new drugs backed in EU

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links